Table 1.
Baseline characteristics stratified by cohorts
| n | Age | Sex | WHO PS | Previous SARS-CoV-2* | ||
|---|---|---|---|---|---|---|
| Mean (SD) | Women (%) | 0 to 1, n (%) | 2 to 3, n (%) | n (%) | ||
| All patients | 723 | 59 (12) | 286 (39.6) | 686 (95.4) | 33 (4.6) | 34 (4.9) |
| Sickle cell disease | ||||||
| Hydrea | 31 | 38 (12) | 14 (5.2) | 30 (96.7) | 1 (3.2) | 3 (10.3) |
| Lymphoma | ||||||
| During rituximab±chemotherapy | 46 | 59 (13) | 20 (43.5) | 44 (97.7) | 1 (2.2) | 1 (2.3) |
| <12 mo after rituximab±chemotherapy | 40 | 62 (11) | 17 (42.5) | 38 (95.0) | 2 (5.0) | 0 (0.0) |
| <12 mo after autologous HCT (BEAM)†,‡ | 31 | 58 (12) | 11 (35.5) | 28 (90.3) | 3 (9.7) | 0 (0.0) |
| Multiple myeloma | ||||||
| First-line therapy | 28 | 62 (7) | 12 (42.9) | 26 (92.9) | 2 (7.1) | 1 (3.7) |
| Daratumumab | 52 | 63 (8) | 19 (36.5) | 49 (94.3) | 3 (5.8) | 1 (2.0) |
| IMiDs | 55 | 60 (9) | 21 (38.2) | 54 (98.2) | 1 (1.8) | 6 (10.9) |
| <9 mo after autologous HCT (high-dose melphalan)† | 51 | 61 (7) | 17 (33.3) | 48 (94.1) | 3 (5.9) | 5 (10.0) |
| CLL | ||||||
| Watch and wait | 56 | 65 (8) | 27 (48.2) | 56 (100) | 0 (0) | 3 (5.8) |
| Ibrutinib§ | 38 | 63 (8) | 13 (34.2) | 38 (100 | 0 (0) | 2 (5.3) |
| CML | ||||||
| TKI | 52 | 54 (13) | 26 (50.0) | 51 (98.1) | 1 (1.9) | 2 (3.8) |
| AML and high-risk MDS | ||||||
| Hypomethylating therapy‖ | 19 | 66 (13) | 4 (21.1) | 16 (84.2) | 3 (15.8) | 0 (0.0) |
| High-dose chemotherapy† | 22 | 50 (16) | 11 (50.0) | 20 (90.9) | 2 (9.1) | 1 (5.3) |
| Myeloproliferative disease | ||||||
| Ruxolitinib | 38 | 57 (10) | 16 (42.1) | 38 (100) | 0 (0) | 3 (8.1) |
| Allogeneic HCT | ||||||
| <6 mo after HCT† | 54 | 55 (13) | 21 (38.9) | 48 (88.9) | 6 (11.1) | 1 (2.0) |
| cGVHD | 57 | 57 (10) | 20 (35.1) | 51 (91.0) | 5 (8.9) | 3 (5.7) |
| CAR T-cell therapy | ||||||
| CD19-directed† | 53 | 60 (11) | 17 (32.1) | 53 (100) | 0 (0) | 2 (3.9) |
WHO PS, World Health Organization Performance Status.
*
N IgG ≥ 14.3 BAUs/mL at baseline.
†
See supplemental Table 1 for clinical details.
‡
B-NHL: n = 21; Hodgkin lymphoma: n = 2; T-NHL: n = 8.
§
Plus venetoclax: n = 8; plus obinutuzumab: n = 2.
‖
Hypomethylating therapy: azacitidine (n = 10), azacitidine plus venetoclax (n = 4), decitabine (n = 4), and decitabine plus midostaurine (n = 1).